Meta-analysis applied in estimating diagnostic accuracy from multiple conflicting reports

• Autorzy: Klimek K.
• Języki publikacji: EN

Abstrakty

EN

Reports of diagnostic accuracy often differ. Meta-analysis is a method of summarizing discrepant data on the accuracy of diagnostic tests. It uses logistic transformation and linear regression to produce a summary receiver operating characteristic curve (SROC).

Słowa kluczowe

EN

medical diagnostics; meta-analysis; diagnostic test

PL

diagnostyka medyczna; metaanaliza; test diagnostyczny

• Wydawca: Wydawnictwo Politechniki Łódzkiej
• Czasopismo: Journal of Applied Computer Science
• Rocznik: 2002
• Tom: Vol. 10, nr 2
• Strony: 67--76
• Opis fizyczny: Bibliogr. 22 poz.

Twórcy

autor

Klimek K.

• Departament of Molecular Biology, Biochemistry and Biopharmacy, Medical University of Silesia, Narcyzow 1, 41-200 Sosnowiec, Poland

Bibliografia

• [1] Luderer A.A., Chen Y.T., Soriano T.F., Kramp W.J.,'Carlson G., Сunу C., Sharp T., Smith W., Pettay J., Brawer M.K. and Thiel R.: Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen, Urology, 1995, Vol. 46, pp. 187-194.
• [2] Littenberg B., Moses L.E., Rabinowitz D.: Estimating diagnostic accuracy from multiple conflicting reports: A new meta-analytic method, Medical Decision Making , 1993, Vol. 13, pp. 313-321.
• [3] Les Irwing MBBCH, Tosteson A.N.A., Gatsonis C , Lau J.M.D., Colditz G.,Chalmers T.C. and Mosteller F.: Guidelines for meta-analyses evaluating diagnostic tests, Annals of Internal Medicine, 1994, Vol. 120, pp. 667-676.
• [4] McClish D.: Analyzing the portion of the ROC Curve, Medical Decision Making, 1989, Vol. 9, pp. 190-195.
• [5] Bangma C.H., Rietbergen J. B. W., Kranse R., Blijenberg B.G., Petterson K.,and Schroder F.H.: The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population, Journal of Urology, 1997, Vol. 157, pp. 2191-2196.
• [6] Catalona W.J. , Smith D.S., Wolfert R.L., Taang J., Rittenhouse H.G., Ratliff T.L. and Nadler R.B.: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening, JAMA, 1995, Vol. 274, pp. 214-1220.
• [7] Chen Y.T., Luderer A. A., Thiel R.P., Carslon G., Cuny C.L., and Soriano T.H.: Using proportions of free to total prostate-specific antigen to predict the probability of prostate cancer, Urology, 1996, Vol. 47, pp. 518-524.
• [8] Elgamal A.A. , Comillie F.J., Van poppel H.P., Van de voorde W.M., Mccabe R., Baer L.V.: Free-to-total prostate specific antigen ratio as a single test for detection of significant stage Tic prostate cancer, Journal of Urology, 1996, Vol. 156, pp. 1042-1047.
• [9] Higashihara E., Nutahara K., Kojima M., Okegawa T., Miura I., Miyata A., Kato M , Sugisaki H. Tomaru T.: Significance of serum free prostate specicfic antigenin the screening of prostate cancer, Journal of Urology, 1996, Vol. 156, pp. 1964- 1968.
• [10] Kochańska A.A., Mielniczuk M.T.R., Stojko A. and Kaletka J.: The clinical utility of measuring free-to-total prostate-specific antigen (PSA) ratio and PSA density in differentiating between benign prostatic hyperplasia and prostate cancer, British Journal of Urology, 1998, Vol. 81, pp. 834-838.
• [11] Letran J.L., Blase A.B., Loberiza F.R., Meyer G.E., Ranson S.D., Brawer M. K, (1998) R.epeat ultrasound guided prostate needle biopsy: Use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma, Journal of Urology, 1998, Vol. 160, pp. 426-429.
• [12] Leung H.Y., Lai L.C.,. Day J., Thompson J., Neal D.E., Hamdy F.C.: Serum free prostate-specific-antigen in the diagnosis of prostate cancer, British Journal of Urology, 1997, Vol. 80, pp. 256-259.
• [13] Mione R., Aimo G., Bombardieri E., Cianetti A., Correale M., Barioli P., Barichello M., Terrone C., Massaron S., Seregni E., Marzano D., Abbate J., Pagrliarulo A., Gion M.: Preliminary results of clinical evaluation of the free/total prostate-specific antigen ratio in a multicentric study, Tumori, 1996, Vol. 82, pp. 543-549.
• [14] Morgan T.O., Mcleod D.G., Leifer E.S., Moul J.W. and Murphy G.P.: Prospective use of free PSA to avoid repeat prostate biopsies in men with elevated total PSA, The Prostate Supplement, 1996, Vol. 7, pp. 58-63.
• [15] Prestigiacomo A.F. and Stamey T.A.: Can free and total prostate specific antigen and prostatic volume distinguish between men with negative and positive systematic ultrasound guided prostate biopsies, Journal of Urology, 1997, Vol. 157, pp. 189-194.
• [16] Promotial Materials of firm CIS: A new clinical approach in prostate cancer and benign prostate hyperplasia., Cis bio international, 1995.
• [17] Recker F., Kwiatkowski M. K., Piironen T., Pettersson K., Goepel M. and Tsholl R.: Free to total prostate-specific antigen(PSA) ratio improves the specificity for detecting prostate cancer in patients with prostatism and itermediate PSA levels, British Journal of Urology, 1998, Vol. 8, pp. 532-538.
• [18] Reissigl A., Klocker H., Pointner J, Fink K., Hominger W., Ennemoser O., Strasser H., Colleselli K., Hold L„ Bartsch G.: Usefulness of the ratiofree/total prostate specific antigen in addition to total PSA levels in prostate cancer screening, Urology, 1996, Vol. 48, pp. 62-66.
• [19] Roehrborn C.G., Gregory A., Mcconnell J.D., Sagalowski A.I., and Wians F., jr: Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology, Urology, 1996, Vol. 48, pp. 24-32.
• [20] Toubert M. E., Guillet J., Chiron M„ Meria P„ Role C., Schlageter M. H., Francois H., Borschneck C., Nivelon F., Desgrandchamps F., Rastel D., Cussenot O., Teillac P., Leduc A., Najean Y.: Percentage of free serum prostate-specific antigen: A new tool in early diagnostic of prostatic cancer, European Journal of Cancer, 1996, 32A, pp. 2088-2093.
• [21] Van Cangh P.J., De Nayer F., Sauvage P., Tombal B., Elsen M., Lorge F. et al.: Free to total prostate specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer, The Prostate Supplement, 1996, Vol. 7, pp. 30-34.
• [22] Wians F.H., Roehrbom C.G.: Human prostate gland - update on prostate cancer tests, Dallas Medical Journal, 1996, pp. 461-463.